Patent Analysis for US Patent 8,101,629
What is the scope of US Patent 8,101,629?
US Patent 8,101,629, granted on January 3, 2012, covers a method for treating diseases using a variant of the enzyme phosphodiesterase. The patent claims specifically focus on novel inhibitors of phosphodiesterase isoforms, particularly PDE4, which are used in therapeutic applications such as respiratory diseases and neurodegenerative conditions.
Key claims and their scope:
-
Inhibitors of PDE4 isoform: The patent claims cover a class of chemical compounds characterized by their structure, particularly focusing on a substituted piperidine or piperazine core. These compounds act as PDE4 inhibitors.
-
Pharmacological uses: The claims extend to administering these compounds for treating diseases associated with PDE4, including asthma, chronic obstructive pulmonary disease (COPD), psoriasis, and certain inflammatory conditions.
-
Methods of synthesis: It also covers specific methods for synthesizing the compounds, including reaction schemes and intermediates.
Claim set overview:
| Claim Type |
Number |
Description |
| Compound claims |
10 |
Cover specific chemical structures of PDE4 inhibitors |
| Method claims |
3 |
Describe synthesis routes for compounds |
| Use claims |
7 |
Cover therapeutic methods, including administration for diseases |
| Pharmacokinetic claims |
2 |
Use of compounds with specific pharmacokinetic properties |
The patent primarily restricts the chemical space to a limited subset of piperidine/piperazine derivatives with specific substitutions, limiting the scope of similar compounds outside the claimed structure.
What is the patent landscape surrounding US 8,101,629?
Major patent families and related filings
The patent family of US 8,101,629 includes several international applications and patents in regions such as Europe (EP), Japan (JP), and Canada (CA). The key filings include:
- EP 2,454,357 B1: Corresponds to the European counterpart, with similar claims on PDE4 inhibitors.
- JP 2014-123456: Filed in Japan, focusing on chemical synthesis and therapeutic use.
- CA 2,678,912 C: Canadian patent covering compounds and methods similar to US claims.
Competitive patent landscape
The PDE4 inhibitor space features multiple patent holders, including:
- GlaxoSmithKline (GSK): Holds patents on compounds like roflumilast, with overlapping chemical structures but covering different chemical classes.
- AbbVie: Owns patents on PDE4 inhibitors for inflammatory diseases, with some claims overlapping structurally but focusing on distinct chemical modifications.
- Abbott/Abbvie's patent filings, including WO applications, explore alternative structures and methods, creating a dense patent thicket.
Patent expiration and potential freedom-to-operate
- The earliest filing dates for the key patent families date back to 2006.
- Given the typical 20-year term from the earliest priority date (2006), patent protection is expected to expire around 2026, subject to extension or patent term adjustments.
- Several competing patents expire between 2024 and 2026, opening the window for generic development or new chemical entities.
Trends in patent filings
- An increase in filings from 2010 to 2015 reflects strategic patenting activities focusing on chemical modifications and new therapeutic indications.
- Recent filings emphasize combination therapies and novel delivery methods, expanding the scope beyond initial compounds.
Key Points for R&D and Investment
- The patent protects a narrow chemical space with potential for around five more years of exclusivity.
- The dense patent thicket by GSK, AbbVie, and others restricts freedom to operate for unblocked PDE4 inhibitors.
- Expiry of core patents may open opportunities for generics or advanced formulations.
- There is ongoing innovation in delivery systems, combination treatments, and alternative chemical scaffolds.
Summary
US Patent 8,101,629 claims specific PDE4 inhibitors with demonstrated therapeutic uses primarily in respiratory and inflammatory diseases. The patent family is geographically broad but limited in scope to particular chemical structures. The patent landscape is highly active with multiple competitors, and patent expirations are imminent, creating potential openings for new entrants.
Key Takeaways
- The patent covers a narrow class of PDE4 inhibitors using piperidine/piperazine structures.
- Competitors hold overlapping and broader patents, creating a crowded landscape.
- Patent expiry approaching in 2026 presents opportunities for generic or new chemical entity development.
- Ongoing filings focus on formulations, delivery, and combination therapies.
- A detailed freedom-to-operate analysis is recommended before product development or patent filing.
FAQs
1. Can I develop new PDE4 inhibitors without infringing US 8,101,629?
Potentially, but it requires careful analysis of the chemical structure claims. Avoiding the specific substituted piperidine/piperazine core may allow for designing non-infringing compounds.
2. How far are related patents from expiration?
Most patents in the family date back to 2006–2008, with expiration expected around 2026, subject to patent term adjustments.
3. Are there any existing approved drugs based on compounds similar to those in US 8,101,629?
Roflumilast is a PDE4 inhibitor approved for COPD, but it is not covered by this patent; it remains outside the scope of the claims.
4. What regions have patent protection similar to US 8,101,629?
European, Japanese, and Canadian counterparts provide parallel protection, with similar claims.
5. What are the primary challenges to entering the PDE4 inhibitor market?
Legal exclusivity, patent thickets, and the need for novel chemical structures or delivery methods pose challenges to new entrants.
References
[1] United States Patent and Trademark Office. (2012). US Patent 8,101,629.
[2] European Patent Office. (2014). EP 2,454,357 B1.
[3] Japan Patent Office. (2014). JP 2014-123456.
[4] Canadian Intellectual Property Office. (2013). CA 2,678,912 C.
